Skip to Primary Navigation

Skip to main content

FDA issues warnings to 30 telehealth companies over marketing violations

A photo of a Mounjaro GLP-1 weight loss drug pen and a bathroom floor scale.
Photo: Peter Dazeley/Getty Images

Kevin Kinsella

2 min read
 Click to share on Facebook (Opens in new window/tab) Click to share on Twitter (Opens in new window/tab) Click to share on LinkedIn (Opens in new window/tab) Click to share on WhatsApp (Opens in new window/tab)

The letters warning of false or misleading marketing claims point to a transition from the agency’s traditional complaint-driven oversight to a more proactive monitoring system.

The US Food and Drug Administration (FDA) has issued 30 warning letters to telehealth companies for making false or misleading claims regarding compounded GLP-1 products offered on their websites. 

Sent on February 20 and made public in early March, the letters cite violations including claims implying compounded products are the same

The

, , , , , , , ,